The Latest Breaking News from NVS

Due to a barrage of strong macroeconomic data, the Federal Reserve has expressed the need to keep interest rates elevated. This is expected to keep the market volatile. Amid this backdrop, it might be wise to buy fundamentally strong dividend stocks Johnson & Johnson (JNJ), Novartis (NVS), and ARC Document…

The Fed is expected to keep hiking rates to achieve its target inflation rate. Amid rising volatility, investor sentiment toward dividend investing has been improving. Here are three quality dividend-paying stocks, Novartis (NVS), Bristol-Myers Squibb (BMY), and Canon (CAJ), which will ensure a steady passive income stream in 2023. Keep…

The stock market might remain volatile in the near term amid the still-alarmingly high inflation and the anticipated continuation of rate hikes. Therefore, fundamentally strong Eli Lilly (LLY), Novartis (NVS), Comcast (CMCSA), HCA Healthcare (HCA), and Myers Industries (MYE), which pay steady dividends, might be safe buys now. Read more.

Hot economic data and rekindled price pressures are expected to keep the stock market highly volatile, with the Fed minutes signaling continued rate hikes in upcoming meetings. Amid this backdrop, investing $1,000 in fundamentally sound and dividend-paying stocks Walmart (WMT), Novartis (NVS), and Albertsons (ACI) could make you richer this…

Amid soaring concerns over an impending Fed-induced recession, the stock market could remain volatile in the near future. Against this backdrop, investors could add stable stocks Johnson & Johnson (JNJ) and Novartis (NVS) to their portfolios in 2023 to garner good returns. Read on….

The pharma industry witnessed solid growth amid the pandemic. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth over the coming years. Therefore, investors could consider buying fundamentally sound pharma stocks Johnson & Johnson (JNJ), AbbVie (ABBV), and…

Despite eased inflation, the robust jobs report raised the prospect of progressive rate hikes. With anxiety escalating about the possibility of a Fed-induced recession, the market volatility is expected to remain elevated in the near future. Hence, investors could consider fundamentally sound and stable stocks Novartis (NVS), Descartes Systems (DSGX),…

The stock market witnessed a solid start this year amid improving investors’ optimism. Moreover, experts see increased chances of a soft landing. So, fundamentally strong stocks Merck (MRK), Novartis (NVS), Sysco (SYY), Progress Software (PRGS), and LSI Industries (LYTS) could be solid buys now. These stocks pay consistent dividends. Read…

Despite the recent positive macro data, the recession possibility remains as the Federal Reserve is expected to keep hiking rates until its target is met. So, dividend-paying healthcare stocks Novartis (NVS) and Takeda Pharmaceutical (TAK) could be stable investment options to safeguard your portfolios. These stocks are trading under $100.…

The stock market witnessed a decent rally in January, with cooling inflationary pressures reducing recession fears. However, the Fed’s attempts to bring inflation down to its 2% target could hurt economic growth. Hence, it could be wise to invest in shares of Johnson & Johnson (JNJ), Novartis (NVS), and LCNB…

Although headline inflation has slowed, the Fed will likely keep raising interest rates to attain its 2% target. However, a potential slowdown in monetary policy tightening is opening the path for quality stocks to recover. Therefore, investors should consider buying fundamentally sound stocks Merck & Co. (MRK), Novartis (NVS), and…